DBS analyst Nico Chen maintained a Buy rating on GE Healthcare Technologies Inc (GEHC – Research Report) yesterday and set a price target of $80.00.
Nico Chen has given his Buy rating due to a combination of factors that highlight GE Healthcare Technologies Inc’s strong market position and growth potential. The company is a global leader in the medical equipment sector, with a robust portfolio that includes advanced imaging technologies such as CT, MRI, and PET systems. Their commitment to innovation is evident through increased investments in research and development, particularly in artificial intelligence, which enhances image analysis and workflow efficiency.
Additionally, GE Healthcare is strategically expanding into the contrast medium space, with the introduction of Flyrcado for PET myocardial perfusion imaging. This product offers a significant advantage over current clinical standards due to its longer shelf life, and its recent FDA approval paves the way for commercial success in the US market. Despite potential challenges from tariffs, GE Healthcare’s joint ventures and local manufacturing capabilities in China help mitigate these risks. These factors, combined with a favorable valuation, underpin Nico Chen’s Buy rating with a target price of USD 80.
According to TipRanks, Chen is a 2-star analyst with an average return of 0.1% and a 39.53% success rate. Chen covers the Healthcare sector, focusing on stocks such as AptarGroup, Johnson & Johnson, and Merck & Company.
In another report released on April 23, Piper Sandler also maintained a Buy rating on the stock with a $88.00 price target.